Abstracts

522 – Structural and Functional Insights Into Depulfavirine as an HIV-1 RT Inhibitor

Background Non-nucleoside reverse transcriptase inhibitors (NNRTIs) remain a cornerstone of antiretroviral therapy (ART). Depulfavirine (DPV), the active metabolite of the prodrug elsulfavirine, is a novel NNRTI with favorable pharmacological properties currently under clinical development. While its antiviral potency has been demonstrated, the structural basis of RT inhibition, its biochemical resistance profile, and how DPV behaves…

286 – Safety and Immunogenicity of Autologous DC Vaccines Loaded With Autologous HIV or Conserved Peptides

Background Dendritic cells (DCs) are potent inducers of immune responses and DC-based therapeutic HIV-1 vaccination has led to boosted HIV-specific immune responses and partial viral control in some studies. We therefore evaluated the safety and immunogenicity of autologous monocyte-derived DC vaccines matured with either IL-1β, IL-6, TNFα, and prostaglandin E2 (pgDC) or IL-1β, TNFα, IFNα2b,…

850 – PK and Safety of Twice-Daily Dolutegravir in 3 kg to 20 kg Children With HIV and TB on Rifampicin

Background Available data supporting global guidelines on the pharmacokinetics and safety of twice daily dolutegravir 10mg dispersible tablets (DT) in children 3-20kg with HIV and tuberculosis (TB) co-infection receiving rifampicin is scarce. We evaluated the pharmacokinetics and safety of twice daily dolutegravir 10mg DT in children 3-20kg on rifampicin. Methods We conducted an open-label, sequential non-randomised prospective study in children initiated on a rifampicin-based TB regimen who concurrently…

319 – Waning of Mpox-Specific Antibodies Among MSM Undergoing MVA-BN Vaccination

Background Two-dose vaccination using the MVA-BN vaccine reduces the risk of Mpox among at-risk populations. However, breakthrough cases of Mpox were reported among individuals with suboptimal antibody responses.  Methods This prospective observational study enrolled MSMs scheduled to undergo 2 doses of MVA-BN vaccination to investigate the serological responses. Blood samples were collected at months 1,…

881 – Surveillance Drug Resistance Mutations in Recently Diagnosed Antiretroviral Naive Brazilian People

Background In the present study, we investigated the prevalence of surveillance drug resistance mutations (SDRM) in individuals newly diagnosed with HIV who were starting ART in Brazil.  Methods The WHO HIV Threshold Survey methodology was used. Subjects from six densely populated cities were selected, a sample representative of the Brazilian macro-regions.  Blood samples were collected…

493 – Pharmacokinetic Profile of Multidose Bictegravir Stearate (XV-130) in Rhesus Macaques

Background Long-acting (LA) antiretroviral therapies (ART) have transformed HIV care through reductions in dose frequency and regimen adherence. The significant preference for ultra-long acting (ULA) ART led to the development of monomeric and dimeric integrase strand transfer inhibitor prodrug nanosuspensions. For bictegravir (BIC),  a single injection of the dimeric prodrug nanosuspension (XV-131) into rodents and rhesus macaques (RM) led to sustained plasma BIC…